As a typical neurodegenerative disease, it is the most common form of dementia incurring confusion, disturbance in short-term memory, loss of cognitive function, and mental disorders such as depressions, progressing gradually to death. Amyloid β is useful in measuring Alzheimer’s Disease risk as it is the earliest-detected biomarker that starts aggregating 15-30 years before symptoms start to show. It is possible to delay the progression of the disease by establishing Alzheimer’s disease risk by monitoring biomarkers during the cognitively normal stages, and by taking medication. The effectiveness of medication is known to be higher during the early stage, thus